ArticleMikrochimica acta2026
A one-shot approach for serum vancomycin assessment using fluorescence-based molecularly imprinted polymer nanoparticles.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Novel fluorescence-based molecularly imprinted polymer nanoparticles (MIP NPs) were prepared by incorporating fluorescent thionine within the polymer matrix. Thionine functioned both as a functional monomer and as an internal signaling probe, enabling a direct fluorescence readout without the need for external fluorescent labels. MIP NPs served as the selective recognition element for vancomycin (VA) assessment. VA bound to the selective cavities of the MIP NPs and quenched the fluorescence via static quenching mechanism. The fluorescence intensity decreased with increasing concentrations of VA. For MIP NPs-based fluorescence spectrometry development, 1 mg/mL MIP NPs dispersed in DI water completely interacted with the VA-containing sample. The assay exhibited a linear response ranging from 1.55 to 100 mg/L (LOD = 0.46 mg/L), enabling highly sensitive measurement of low VA levels in serum. The recovery was 97-115%, with within-run precision of 2.7-6.2%. Furthermore, the developed assay shows relatively high selectivity toward VA over other antibiotics/medications, including gentamicin, ampicillin, and acetaminophen. Spiked VA in the serum sample analyzed by MIP NP-based fluorescence spectrometry compared to the particle-enhanced turbidimetric inhibition immunoassay gave less than 12% relative error for all samples, suggesting acceptable accuracy of the proposed method. This assay achieved rapid results within 10 min in a one-shot approach, compared to the multi-step nanoMIP-based ELISA at 90 min. The high binding ability and selectivity of the thionine-based MIP NPs showed promise as a selective material against VA for other applications.
Indexed as
Identifiers
41483245What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.